Blast Crisis
by: Lauren Gillespie MD

Polycythemia
by: Olivia Urbanowicz MD
Ocular Toxoplasmosis
by: Stephanie Winslow MD

Aspergilloma
by: Matthew M. Mannion
MS4

Fallopian Tube Torsion
by: Andrea Comiskey MD
History of Present Illness
The patient is a female in her early 20s who was referred to the emergency department (ED) by her primary care provider, who saw her earlier that day for knee pain. The patient has had pain in bilateral knees for the past two days and describes it as deep, aching, and constant. The pain is worse with ambulation and slightly improved with acetaminophen and ibuprofen. She denies any recent trauma. She has had some associated hand and ankle arthralgias as well. Earlier today, her primary care provider prescribed ketorolac and prednisone and ordered outpatient laboratory studies. She was then advised to immediately present to the ED after labs resulted and were noted to have a profoundly elevated white blood cell count. Review of systems at time of presentation to the ED is negative for headaches, vision changes, night sweats, weight loss, fever, chills, nausea, vomiting, chest pain, or dyspnea.

Physical exam
The patient is a young female in no apparent distress, well-nourished without cachexia. Head, ears, eyes, nose, and throat exam reveals moist mucous membranes. Cardiopulmonary examination is unremarkable. Abdominal exam is benign without focal tenderness or distension. She has warm, dry skin without rash, petechiae, or ecchymoses. Musculoskeletal exam demonstrates no swelling, tenderness, or limitation of range of motion of bilateral knees. Neurologic exam reveals appropriate mental status, grossly intact cranial nerves, normal ambulation, and spontaneous movement of all four extremities.

Diagnostics

<table>
<thead>
<tr>
<th>Differential:</th>
<th>Myelocytes 10.5%</th>
<th>Metamyelocytes 3.0%</th>
<th>Bands 10%</th>
<th>Neutrophils 30.5%</th>
<th>Lymphocytes 4.5%</th>
<th>Monocytes 1.5%</th>
<th>Eosinophils 1.5%</th>
<th>Basophils 0.5%</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCV</td>
<td>88.9</td>
<td>MCH</td>
<td>25.8</td>
<td>Phosphorus</td>
<td>4.2</td>
<td>Magnesium 2.1</td>
<td>Haptoglobin</td>
<td>&lt;30 (44-215 mg/dL)</td>
</tr>
<tr>
<td>LDH</td>
<td>1,753</td>
<td>(140-280 units/L)</td>
<td>Uric acid</td>
<td>6.5 (3.8-8.7 mg/dL)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>D dimer</td>
<td>6.51</td>
<td>CRP</td>
<td>24.8 (1-10 mg/L)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fibrinogen</td>
<td>270 (218-406)</td>
<td>INR</td>
<td>1.2, PTT 36.3</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hepatic</td>
<td></td>
<td>function panel</td>
<td>AST</td>
<td>50, bilirubin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Blood cultures</td>
<td></td>
<td></td>
<td>bilirubin</td>
<td>normal</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Knee X rays revealed no joint effusion or evidence of acute bony abnormality.

Hospital Course
The bone marrow transplant (BMT) team had been pre-notified about the patient and admitted her to their service. They reviewed her peripheral smear and found it concerning for chronic myelogenous leukemia (CML) with blast crisis. She underwent bone marrow biopsy, flow cytometry, and chromosome analysis which were consistent with primary B-cell acute lymphoblastic leukemia, with positivity for the Philadelphia chromosome with BCR-ABL translocation t(9;22). She was started on hydroxyurea for cytoreduction; fluids for rehydration and hyperleukocytosis; Dasatinib for targeted therapy; steroids and allopurinol for tumor lysis syndrome prophylaxis; and bacterial, viral, and fungal antimicrobial prophylaxes.

It was at first uncertain whether this represented a de novo malignancy or whether it arose from underlying long-standing CML, however, further chart review revealed that the patient had actually had a leukocytosis with abnormal myeloid precursors for months to years, more consistent with primary CML. Lumbar puncture was performed to evaluate for malignancy and initiate intrathecal chemotherapy with methotrexate and hydrocortisone. The patient’s knee pain persisted throughout hospitalization and was thought to be due to her underlying malignancy. She was ultimately discharged after her hyperleukocytosis improved with a plan to continue scheduled chemotherapy and undergo evaluation for a bone marrow transplant.

Discussion
Pathophysiology
Chronic myelogenous leukemia (CML) is a hematologic malignancy and myeloproliferative disorder that occurs due to a translocation between the long arms of chromosomes 9 and 22, resulting in the pathologic Philadelphia chromosome, so-named because it was discovered in Philadelphia. This translocation results in a fusion gene (BCR-ABL) that encodes a constitutively active tyrosine kinase.
kinase known as the Bcr-Abl1 protein. This protein causes the uncontrolled production of dysregulated, dysfunctional cells of myeloid lineage in various stages of development, particularly matured and maturing granulocytes (figure 1). Although almost all CML cases are associated with the Philadelphia chromosome, the Philadelphia chromosome can also be present in acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML), and its presence is not sufficient for definitive CML diagnosis.

Epidemiology
CML accounts for approximately 15% of leukemia diagnoses in the Western Hemisphere, with 1-2 cases per 100,000 people diagnosed annually. Its prevalence is increasing due to improving survival rates with the development of more effective therapies in recent years. CML is most common in adults with a median age at diagnosis of 66, and only 2% of cases are diagnosed in adolescents and children. Risk factors for CML include exposure to ionizing radiation, gender (slightly more common in males), and older age. As the disease progresses, patients may present in acute lymphocytic leukemia (ALL) and acute myelogenous leukemia (AML), and its presence is not sufficient for definitive CML diagnosis.

Clinical Presentation
Patients with CML present in one of three phases: chronic phase, accelerated phase, or blast phase. Ninety percent of patients with CML are diagnosed in the chronic phase, often incidentally due to an abnormal complete blood count performed for other reasons, though most do report at least one symptom at the time of diagnosis. As the disease progresses, patients may enter the accelerated phase, and then the blast phase, which are diagnoses made using laboratory and pathology studies (table 1). Patients in the accelerated phase and blast phase are much more likely to have treatment-resistant disease and a poorer prognosis.

Early in the disease course, patients may experience generalized symptoms such as malaise, weight loss, fever, and abdominal discomfort due to developing hepatosplenomegaly associated with extramedullary hematopoiësis. As the disease becomes more advanced, patients are more likely to experience bone pain, lymphadenopathy, and skin infiltration. Some of the more commonly reported symptoms at the time of CML diagnosis are summarized in table 2. A variety of additional rare presentations of CML have been reported in the literature including spontaneous splenic rupture or infarct, avascular necrosis, intracranial hemorrhage, spontaneous soft tissue hematoma, and other symptomatic bleeding and ischemic conditions. Patients in blast phase may present with hyperleukocytosis (WBC count >50-100 x 10^9/L) leading to leukostasis, which is a true oncologic emergency in which white blood cell infiltrates in the microvasculature cause tissue ischemia. The pathophysiologic mechanisms underlying leukostasis are not completely understood, but are thought to include increased blood viscosity as well as endothelial damage. Symptoms of leukostasis can involve any organ system, most commonly the central nervous system, lungs, and kidneys, and may include cerebrovascular accident, confusion, coma, acute respiratory distress, and renal failure in addition to retinal hemorrhage, priapism, tinnitus, myocardial ischemia, bowel infarction, and venous thrombosis. Eighty percent of patients presenting with leukostasis have fever, likely from heightened inflammation or concurrent infection.

Diagnostic Workup
Patients with CML frequently present with leukocytosis ranging from 10-500 x 10^9/L. Careful examination of the white blood cell differential is extremely important, since leukocytosis can easily be attributed to infection or inflammation. In CML, the differential will show a left-shift with predominance of neutrophils and the presence of bands, myelocytes, metamyelocytes, promyelocytes, and blasts. Absolute basophils or eosinophils may also be increased. Thrombocytosis or thrombocytopenia may be present, and anemia is present in about one-third of patients. A peripheral smear is also helpful in the ED to identify abnormal cellular morphology. Ultimately, a bone marrow biopsy with advanced pathology and cytogenetic testing are necessary to make the diagnosis. If hematologic malignancy is suspected in the ED,
History of Present Illness

The patient is an otherwise healthy female in her late 50s who presents to the emergency department (ED) with a chief complaint of bilateral posterior neck pain, odynophagia, and dysphagia with solid foods over the previous two weeks. She describes the neck pain as constant, 10/10 pain which has been progressively worsening, is exacerbated by movement, and is not alleviated by Tylenol or Ibuprofen. She also vomited twice a few days ago. She denies fever, nausea, abdominal pain, dysuria, hematuria, constipation, or diarrhea.

Physical exam

The patient is a thin female in no acute distress. Her pupils are equal, round, and reactive to light. Cranial nerves are intact, and her voice is clear without aphasia or dysphonia. She has 5/5 strength and intact sensation throughout bilateral upper extremities. No trismus is appreciated. Mucous membranes appear dry. Range of motion of the neck is limited, but there is no nuchal rigidity. She is exquisitely tender to palpation over the paraspinal musculature and soft tissues of the neck. Cardiovascular, pulmonary, and abdominal exam are within normal limits.

Notable Diagnostics

- Calcium 9.5, phosphate 3.4, albumin 3.7
- HIV 1+2 nonreactive

Hospital Course

The patient was given ketorolac with subsequent improvement in her neck pain and normalization of the range of motion of her neck. A nasopharyngeal scope was performed at bedside which showed no edema, masses or abnormalities of the vocal cords, epiglottis, or posterior pharynx. Contrasted CT imaging of the neck was normal. However, lab workup revealed an incidental finding of polycythemia. Although the workup for her neck pain was negative and her pain significantly improved, the patient was admitted to hospital medicine for further evaluation and management of her incidental polycythemia.

Hematology was consulted and recommended outpatient transthoracic echocardiography to evaluate for a shunt, carboxyhemoglobin, and JAK 2 level. Phlebotomy of 500mL was performed with replacement of crystalloid due to the extent of her polycythemia. The patient was discharged two days later, without any apparent complications, with plans to follow up in the outpatient setting with hematology for likely primary polycythemia. At that time, polycythemia vera and EPO-driven polycythemia were thought to be the most likely etiologies.

Results later demonstrated a normal echocardiogram, carboxyhemoglobin of 3.5% (normal value < 2% as the patient is not a smoker), normal JAK 2, normal EPO levels, negative testing for BCR-ABL, and CT abdomen/pelvis negative for splenomegaly. She declined bone marrow biopsy, so the etiology of her polycythemia remains unknown. She continues to be managed with intermittent phlebotomy. Since her initial visit, she has also had seizures and was found to have subdural hygromas and evidence of prior CVAs. She has also had intermittent ED visits for neck pain, which have been thought to be secondary to occipital neuralgia.

Discussion

Hospital Course

The patient was given ketorolac with subsequent improvement in her neck pain and normalization of the range of motion of her neck. A nasopharyngeal scope was performed at bedside which showed no edema, masses or abnormalities of the vocal cords, epiglottis, or posterior pharynx. Contrasted CT imaging of the neck was normal. However, lab workup revealed an incidental finding of polycythemia. Although the workup for her neck pain was negative and her pain significantly improved, the patient was admitted to hospital medicine for further evaluation and management of her incidental polycythemia.

Hematology was consulted and recommended outpatient transthoracic echocardiography to evaluate for a shunt, carboxyhemoglobin, and JAK 2 level. Phlebotomy of 500mL was performed with replacement of crystalloid due to the extent of her polycythemia. The patient was discharged two days later, without any
Results later demonstrated a normal echocardiogram, carboxyhemoglobin of 3.5% (normal value < 2% as the patient is not a smoker), normal JAK2, normal EPO levels, negative testing for BCR-ABL, and CT abdomen/pelvis negative for splenomegaly. She declined bone marrow biopsy, so the etiology of her polycythemia remains unknown. She continues to be managed with intermittent phlebotomy. Since her initial visit, she has also had seizures and was found to have subdural hygromas and evidence of prior CVAs. She has also had intermittent ED visits for neck pain, which have been thought to be secondary to occipital neuralgia.

**Polycythemia**

Polycythemia, also called erythrocytosis, is an abnormally elevated level of hemoglobin or hematocrit in the circulating peripheral blood. Polycythemia can be classified into relative polycythemia, which is generally secondary to volume depletion, and absolute polycythemia, which can arise from primary myeloproliferative disorders or in response to hypoxia from a number of secondary causes. Although the majority of patients are found to have polycythemia incidentally, a small percentage present to the ED with acute thrombotic events, which are a rare but well-recognized complication of both primary and secondary polycythemia.

**Pathophysiology and Definitions**

Polycythemia is a laboratory-based diagnosis, defined as hemoglobin >16.5g/dL in men, >16g/dL in women or hematocrit >49% in men, >48% in women. It is important to recognize that both hemoglobin and hematocrit are not direct measures of red blood cells (RBCs). Instead, they more accurately depict the percentage or relative value of the circulating blood volume that is comprised of RBCs. A patient can have a relative polycythemia resulting from decreased plasma volume (hemococoncentration), most commonly due to dehydration, vomiting, diarrhea or diuretic use. Although patients with polycythemia often have an elevated RBC count, the RBC count alone can be appropriately elevated in physiologic response to anemia, and therefore must be elevated in conjunction with an elevated hemoglobin or hematocrit in order to be diagnostic.

Absolute polycythemia (a true increase in red blood cell mass) can be further divided into primary and secondary causes. Primary polycythemias are caused by mutations in the RBC progenitor cells that result in an increased total RBC mass. The most well-characterized of these entities is polycythemia vera (PV), which is due to a JAK2 mutation. However, many other myeloproliferative disorders can result in primary polycythemia.

Secondary polycythemia is an increased RBC mass in response to elevated serum erythropoietin (EPO) levels, which is usually secondary to tissue hypoxia. Common preceding conditions leading to secondary polycythemia include smoking, chronic obstructive pulmonary disease, obstructive sleep apnea, and carbon monoxide exposure. Patients residing at high altitude live in a relatively hypoxic environment and can demonstrate elevated, non-pathologic baseline levels of both hemoglobin and hematocrit. In order to account for this, the reference upper limit for hemoglobin should be increased by approximately 1.0g/dl for patients living between 7500 and 10000 feet of altitude and by approximately 2.0g/dl for patients living at 10000-12000 feet. EPO is produced by the kidneys, so patients with chronic renal insufficiency or a subacute insult to the renal parenchyma can also present with a secondary polycythemia. Secondary polycythemia may also result from EPO levels which are inappropriately elevated secondary to a paraneoplastic syndrome from an EPO-secreting malignancy. The malignancies most commonly implicated include renal cell carcinoma, hepatocellular carcinoma, and pheochromocytoma. Finally, secondary polycythemia can be seen in athletes who undergo autologous blood transfusions or exogenous EPO administration (also known as blood doping). Regardless of the cause of an absolute polycythemia, the increased RBC mass leads to hyperviscosity of the blood, placing the patient at increased risk of thrombotic events.

**Clinical Presentation**

In the Emergency Department, polycythemia most often presents as an incidental finding. It is important to attempt to differentiate between relative and absolute polycythemia, as only the latter confers a significant thrombotic risk. This can be accomplished by treating with intravenous fluids and retesting; improvement following fluid resuscitation indicates a relative polycythemia. In addition to volume depletion, chronic carbon monoxide exposure (such as smoking history or environmental exposures), chronic hypoxia, and occult malignancy should all be considered during the initial evaluation of a patient with undifferentiated polycythemia.

![Figure 1: Erythromelalgia](image)

Patients with absolute polycythemia may present with symptoms of hyperviscosity (see table). Specific symptoms in polycythemia vera include pruritus after bathing (either with hot or cold water) and erythromelalgia (figure 1). Some studies suggest these symp-
Ocular Toxoplasmosis

Stephanie Winslow
University of Cincinnati R3

History of Present Illness
The patient is a male in his late teens who presents to the emergency department with a chief complaint of right eye redness, pain, and blurred vision for one week. There are no associated floaters or photophobia. Additional complaints include rash and nausea with one episode of vomiting. The patient is originally from Nicaragua and moved to the United States one month ago. He was previously seen by a physician in Nicaragua for the same complaint and was diagnosed with an eye infection, but he is not sure what type. He was started on trimethoprim-sulfamethoxazole, pyrimethamine, and steroid eye drops. The patient has worked with fiberglass in the past, but is unsure of any ocular foreign bodies. He is not a contact lens wearer and denies any history of trauma.

Past Medical History/Past Surgical History
None

Medications
Trimethoprim-sulfamethoxazole, pyrimethamine, ophthalmic dexamethasone drops

Allergies
None

Physical Exam
The patient is a well-appearing male in no acute distress. Eye exam reveals diffuse injection of the conjunctiva of the right eye. Pupils are 4mm, equal, and briskly reactive to direct and consensual light stimulation. Slit lamp exam reveals no fluorescein uptake, foreign body, or cell and flare. The iris and lens appear normal. Left eye visual acuity is 20/25. Right eye visual acuity is counting fingers at 5 feet. Cardiovascular exam is remarkable for tachycardia. Pulmonary, abdominal, musculoskeletal exams are unremarkable. The skin exam shows a maculopapular rash of the trunk. Neurologic exam is within normal limits.

Notable Diagnostics
AST 55, ALT 66, Total Bilirubin 0.5
WBC 8.0, HIV non-reactive
Chest X-ray: No acute cardiopulmonary abnormality

Hospital Course
Ophthalmology was consulted from the emergency department. On their dilated fundoscopic exam they observed white chorioretinal lesions in the posterior pole near the fovea and along the superior arcade. Given the patient's history of treatment with trimethoprim-sulfamethoxazole, pyrimethamine, and topical dexamethasone, ophthalmology felt the patient's presentation was most consistent with a diagnosis of ocular toxoplasmosis. However, on their exam ocular toxoplasmosis did not appear active, and recommended testing for syphilis and tuberculosis. In the ED, the patient was initiated on prednisolone eye drops, trimethoprim-sulfamethoxazole was continued for one week, and pyrimethamine was discontinued. The patient was seen by ophthalmology in follow-up as an outpatient one week later. His ocular lesions were found to be stable, consistent with inactive ocular toxoplasmosis. The patient ultimately returned to Nicaragua and was lost to further follow-up.

Discussion
Toxoplasma gondii Life Cycle and Epidemiology
Toxoplasma gondii is a ubiquitous obligate intracellular protozoan parasite that infects many species, including humans, and is the most common cause of infectious posterior uveitis in the world.1 Cats are the definitive or primary hosts for T. gondii, and they are the only organism in which the T. gondii sexual reproductive cycle takes place. Infected cats release toxoplasma oocysts in their feces. Intermediate hosts, such as pigs or humans, become infected with toxoplasma by consuming food or water contaminated with cat feces, eating undercooked meat containing tissue cysts, through blood transfusion or organ transplant, or congenitally from mother to fetus.2 (Figure 1) Once ingested by an intermediate host the oocysts then become infectious tachyzoites, which multiply rapidly by an asexual reproductive cycle, causing local tissue destruction and inflammation. Under the pressure of a competent immune system, tachyzoites become bradyzoites, a dormant version, which form tissue cysts that can persist for the life of the host.

Approximately 25-30% of the human population is infected with T. gondii, however, rates of seropositivity for this infection vary greatly based on socioeconomic factors, hygiene, and climate, with higher rates of seropositivity in warmer geographic locations.1 In the United States, it is estimated that approximately 1 million people are seropositive for T. gondii, and approximately 20,000 people have ocular toxoplasma lesions.3

Clinical Presentation
Acute acquired infection with T. gondii (toxoplasmosis) in immunocompetent patients is often asymptomatic, however, approximately 10% of patients will develop a nonspecific flu-like illness, which is usually self-limited. The most common systemic finding in immunocompetent patients with acute toxoplasmosis is painless, non-suppurative lymphadenopathy, usually cervical or occipital. Rarely, toxoplasmosis can present as myocarditis, polymyositis, pneumonitis, hepatitis, or encephalitis in immunocompetent patients.4

In immunocompromised patients, toxoplasmosis is often symptomatic and can be life-threatening. It usually occurs as a reacti-
Ocular Toxoplasmosis

Ocular toxoplasmosis typically presents as posterior uveitis, with the potential for inflammation of the choroid, retina, and optic nerve. It occurs due to both congenital and acquired infections. Patients may experience floaters and vision loss, and vision can be rapidly and profoundly affected, with up to 24% of patients presenting with visual acuity worse than 20/200 at some point over the course of their disease. Clinical diagnosis of ocular toxoplasmosis is highly dependent upon the dilated ophthalmologic exam. The classic funduscopic finding for ocular toxoplasmosis is a fluffy, white, focal, necrotizing retinitis. The active lesion is often obscured by severe inflammation of the vitreous, causing a “headlight in the fog” appearance (Figure 2). Significant scarring of the retina, particularly in the macula, can also be seen (Figure 3).

Differential diagnosis for the presentation of ocular toxoplasmosis includes other causes of posterior uveitis such as cytomegalovirus, herpes simplex, herpes zoster, tuberculosis, and syphilis. Alternatively, one must consider retinal detachment and diseases of the retinal vasculature in the presentation of patients with vision loss.

Diagonstics

If toxoplasmosis is suspected, the diagnostic testing strategy varies depending on whether the patient is immunocompetent, immunocompromised, pregnant, or newborn. Detection methods include both direct detection (using PCR or immunohistochemistry tests) and indirect detection (using serology tests for IgG, IgM, and IgA antibodies). Serum IgG and IgM antibodies to T. gondii typically will begin to develop within 7-14 days after the initial infection. Serum IgM antibody positivity is the preferred marker of acute infection with toxoplasmosis. However, a high false positive rate limits its use, and its greatest value lies in the fact that a negative IgM antibody essentially rules out a recently acquired toxoplasma infection. In immunocompromised patients, direct detection of toxoplasma using PCR tests in the affected body fluid (blood, bronchoalveolar lavage, pleural, peritoneal, cerebrospinal, or ocular fluids) is often an important diagnostic aid. The diagnosis of ocular toxoplasmosis is often clinical, but in the case of an uncertain diagnosis or inadequate response to treatment, serology testing or sampling of ocular fluids for direct testing may be necessary. If there is any concern for involvement of the central nervous system, CT and MRI imaging of the brain and spine are necessary, and may show characteristic “ring-enhancing” lesions.

Treatment

Toxoplasmosis, including ocular toxoplasmosis, in the immunocompetent patient is usually self-limited and not treated unless symptoms are severe or prolonged. Strict indications for treatment of ocular toxoplasmosis in the immunocompetent patient depend on the size of the lesion (greater than two times the diameter of the optic disc) or the location of the lesion adjacent to the optic disc to minimize vision loss.

Empiric treatment for toxoplasmosis in non-pregnant patients, including neonates and immunocompromised patients, includes pyrimethamine, sulfadiazine, and folic acid. The duration of treatment is variable. Some studies have suggested that replacing pyrimethamine and sulfadiazine may also be an adequate treatment regimen. In pregnant patients with active infection, spiramycin alone is used in the first trimester. Pyrimethamine and sulfadiazine can be started after the first trimester. Steroids, which are thought to help to suppress inflammation in the eye, are typically added in treatment of ocular toxoplasmosis. The ideal timing, dosage, and indication for steroid use is unclear and there are a wide variety of practice patterns. Most clinicians opt to delay the initiation of steroids at least 1-3 days after starting antiparasitic agents, since steroids can worsen optic lesions without concomitant antiparasitic use.
History of Present Illness

The patient is a male in his late 40s with a past medical history of pulmonary sarcoidosis who presents reporting hemoptysis upon waking each morning for the past three days. He describes the hemoptysis as one to two small teaspoons of blood mixed into his sputum. Last night he coughed up a larger amount of blood, about 3-4 tablespoons, and developed pleuritic chest pain, which prompted him to come to the Emergency Department. He continues to expectorate blood-mixed sputum at bedside. His pulmonologist prescribed levofloxacin for a possible bacterial infection, which he has been taking for the past three days. He endorses his baseline dyspnea and chest tightness, but denies fever, fatigue, nausea, vomiting, melena, hematochezia, or other changes in bowel or urinary habits.

Past Medical History
Pulmonary sarcoidosis, seasonal allergies

Past Surgical History
Right lung biopsy in 2015

Medications
Albuterol PRN, azathioprine 50 mg daily, budesonide-formoterol daily, cetirizine 10 mg daily, levofloxacin 500 mg daily, prednisone 20 mg daily

Allergies
None

Physical Exam
The patient is a well-appearing male in no acute distress. His oropharyngeal exam is unremarkable with no evidence of blood, erythema, or swelling in the posterior oropharynx or in the nares bilaterally. He has unlabored breathing with diffuse expiratory wheezes appreciated bilaterally but otherwise without focality. Auscultation of the heart reveals no murmurs, rubs, or gallops, and abdominal exam is unremarkable. All four extremities are symmetric, warm, well-perfused, and without edema. His skin is dry with no rashes or peripheral edema noted.

Diagnostic Tests
Venous blood gas: pH 7.38, pCO₂ 50 HCO₃ 29, BE 3.1

CT Pulmonary Angiography:
1. No acute pulmonary embolism. 2. Posterior left upper lobe cavity with central soft tissue mass surrounded by a crescent of air suggestive of an aspergilloma. Some linear high-density foci within the cavitary lesion may represent areas of active extravasation or abnormal irregular pulmonary arteries in the setting of hemoptysis. 3. Background of sarcoidosis. 4. Enlarged pulmonary artery can be seen in the setting of pulmonary hypertension.

Hospital Course
Given the patient’s risk factors for pulmonary embolism, he underwent CT pulmonary angiography which showed no evidence of pulmonary embolism but did reveal a 5.5 x 3 cm cavitary lesion consistent with likely aspergilloma with active bleeding into the left upper lung. He continued to have hemoptysis in the ED and was admitted to the medicine stepdown unit for close monitoring. The infectious disease (ID) team was consulted and recommended empiric treatment with voriconazole. The interventional pulmonology (IP) team performed a bronchoscopy which showed a cavitary lesion in the left upper lobe with a fungal ball. Bronchoalveolar lavage (BAL) with lung biopsy showed fungal hyphae morphologically consistent with aspergillus species, without evidence of vascular or tissue invasion. Fungal cultures eventually grew Aspergillus fumigatus. The remainder of the patient’s infectious workup was negative, including evaluation for HIV, tuberculosis, histoplasma, and cryptococcus.

Following his bronchoscopy and biopsy, the patient developed an increased oxygen requirement but was eventually weaned down to nasal canula oxygen at 1 liter per minute. The patient was evaluated by thoracic surgery for possible surgical resection of his aspergilloma, but unfortunately was not a candidate for intervention.
due to his severe pulmonary disease. The patient was discharged on home oxygen therapy and voriconazole, with plan to continue voriconazole indefinitely. Two months after this hospitalization, he had another episode of hemoptysis and underwent repeat bronchoscopy with voriconazole instillation. This procedure was repeated about one month later and since then, he has had no further hemoptysis recorded in our electronic medical record.

Discussion
Aspergillosis Pathophysiology and Risk Factors
Aspergillosis refers to a spectrum of disease caused by the aspergillus species of fungus, most commonly Aspergillus fumigatus (figure 1). Aspergillus is ubiquitous in our environment, living in soil and decomposing vegetation, and we are constantly inhaling its spores. Our immune systems have evolved to control the growth of aspergillus and prevent inflammation and injury from its presence, so that systemic fungal disease is uncommon. Disorders of immunity, however, can place patients at risk for infections due to aspergillus. The type of aspergillus infection that occurs depends on host risk factors and most commonly involves the respiratory tract, although disseminated forms of the disease can occur as well.

The most feared presentation of aspergillosis is invasive pulmonary aspergillosis (IPA) which is classically seen in severely immunocompromised patients. Risk factors for IPA include severe or prolonged neutropenia, defects in cell-mediated immunity (such as human immunodeficiency virus), immunosuppressive therapy, bone marrow transplant, and solid organ transplant. Patients with prolonged stays in intensive care units have also been recently identified as a population at risk for IPA, particularly those with chronic obstructive pulmonary disease with steroid use, structural lung disease, acute respiratory distress syndrome, and impaired mucociliary clearance following infection. Multiple respiratory viral infections have been associated with IPA including avian flu, influenza A and B, respiratory syncytial virus, and COVID-19. These viruses are thought to cause epithelial damage that then allows invasion by colonizing aspergillus species.

There are multiple chronic forms of pulmonary aspergillosis that occur in patients with underlying pulmonary disease, in some cases leading to inflammation, tissue destruction, fibrosis, and worsening pulmonary function. The most common manifestation of chronic pulmonary aspergillosis is aspergilloma, also known as a mycetoma or fungus ball, in which the fungus is able to grow inside a pre-existing cavitary lesion (secondary to chronic obstructive pulmonary disease, prior tuberculosis, sarcoidosis, or other causes). An association between sarcoidosis and aspergilloma has been demonstrated in the literature, with an estimated 0.7-5% of sarcoidosis patients being affected by aspergilloma.

Another distinct presentation of aspergillosis is allergic bronchopulmonary aspergillosis (ABPA), which occurs almost exclusively in patients with asthma and cystic fibrosis due to a hypersensitivity reaction to Aspergillus species in the lungs. ABPA leads to chronic immune activation and presents with fleeting pulmonary infiltrates, worsening of reactive airway disease, and bronchiectasis. There are multiple pulmonary aspergillosis overlap syndromes, and patients may develop more than one manifestation of aspergillosis or may progress from one form to another. For example, patients with ABPA and chronic pulmonary aspergillosis have gone on to develop fungal balls and IPA. A summary of the spectrum of pulmonary aspergillosis according to risk factor is provided in Table 1.

The remainder of this review will focus on pulmonary aspergilloma, since that is the most common manifestation of pulmonary aspergillosis and the entity with which our patient presented.

Aspergilloma - Clinical Presentation
Hemoptysis is the most common clinical manifestation of aspergillomas, and aspergillomas remain one of the leading causes of hemoptysis worldwide (along with tuberculosis and lung abscesses). In case series describing aspergilloma, the incidence of hemoptysis has been reported to range from 54%-87.5%, with up to 30% of patients experiencing massive fatal hemorrhage. The hemoptysis is thought to be secondary to direct invasion of the capillaries lining the cavity wall, endotoxin-mediated inflammation, or mechanical irritation of exposed vessels within the cavity. Symptoms can also include malaise, weight loss, chest pain, dyspnea, chronic cough, and, rarely, fever. Aspergillomas may remain stable, or they may grow, causing pneumonia, pulmonary fibrosis, and disseminated disease (such as IPA).

Aspergilloma - Diagnosis
The diagnosis of aspergilloma should be considered in a patient with hemoptysis and other risk factors, and the first step for diagnosis in the emergency department is identifying radiographic evidence of a rounded fungal ball inside a cavity on chest X-ray or computed tomography. Two radiographic signs may aid in the diagnosis: the air crescent sign, which is a crescent-shaped air space separating the fungal ball from the cavity wall, and Monod sign, which is characterized by the change in position of the fungal ball depending on the patient’s position. If a fungal ball is seen on imaging, the diagnosis can be confirmed with serum tests, which may include Aspergillus-specific IgG or IgE antibodies. Aspergillus cell wall components (such as galactomannan) may also be found in BAL fluid. A fungal culture positive for aspergillus species may aid in the diagnosis, but is not sufficient for diagnosis on its own since...
History of Present Illness
The patient is a 10-year-old female who presents to the emergency department for a 2-day history of abdominal pain. The pain started in the periumbilical region and migrated to the right lower quadrant. She associates her pain with mild nausea, non-bilious and non-bloody vomiting, constipation and a low-grade temperature. The patient denies any aggravating or alleviating factors, as well as any associated dizziness, headaches, chest pain, shortness of breath, urinary frequency or dysuria, bloody stools, weight loss, back pain or additional symptoms.

Past Medical History
Cardiac murmur, ADHD. Immunizations are up to date.

Past Surgical History
None

Medications
Methylphenidate 10mg by mouth daily, Miralax 8.5 gm by mouth PRN

Allergies
No known drug allergies

Social History
Lives at home with parents

Physical Exam
The patient is a well-developed, well-nourished young female who is oriented to person, place, and time and in no acute distress. Her abdomen is soft with right lower quadrant tenderness without rebound, rigidity or guarding. The remainder of her exam, including HEENT, cardiopulmonary, skin, extremities, and neurologic exam was unremarkable.

Diagnostic Tests
RLQ ultrasound: Appendix not visualized; no secondary signs of appendicitis noted. Abnormal configuration of the right ovary with what appears to be a serpiginous tubular structure extending from the ovary towards the uterus which may represent abnormal configuration of the fallopian tube.

Urinalysis: normal

Pelvis ultrasound with doppler: Situated between the right ovary and the uterus there is a dilated anechoic tubular structure which appears to be folded upon itself. This is concerning for torsion of the right fallopian tube.

Hospital Course
In the emergency department, the providers were initially concerned for appendicitis or ovarian torsion since the patient had tenderness in the right lower quadrant coupled with nausea and vomiting. The patient underwent a dedicated right lower quadrant ultrasound to assess for appendicitis, which did not visualize the appendix but showed abnormal appearance of the right ovary with a serpiginous structure extending from the ovary to the uterus. The patient then underwent a dedicated pelvis ultrasound which demonstrated a tubular structure twisted upon itself, concerning for fallopian tube torsion.

Gynecology evaluated the patient and recommended urgent surgical exploration. Intra-operative findings included a visualized appendix with normal appearance; however, the right fallopian tube was noted to have twisted upon itself twice, with edema, loss of architecture and dusky appearance concerning for irreparable tissue damage. The patient underwent an uncomplicated right salpingectomy and cystectomy on the right. A fluid-filled mass within the tube was evacuated and after pathologic evaluation, the contents were found to be consistent with a simple cyst. The patient was discharged in stable condition from the post-operative anesthesia care unit. Two weeks after discharge she was noted to be doing well with complete resolution of her symptoms.

Discussion
Epidemiology
Isolated fallopian tube torsion is a rare pathology, first described by John Bland-Sutton in 18901 and currently estimated to affect approximately 1 in 1.5 million women.2 Women of child-bearing age tend to present most commonly, and there are very few cases in the literature reporting this pathology in premenarchal patients.3 It is also extremely rare in postmenopausal females, and the lower incidence in this population is thought to be due to fallopian tube hypotrophy and decreased blood supply.1

Pathophysiology
Multiple mechanisms, both intrinsic and extrinsic to the fallopian tube, are proposed to cause isolated fallopian tube torsion (table 1).
In our patient, a cyst-like structure in the fimbriated half of the fallopian tube was found during laparoscopy. This may have been a hydatid cyst of Morgagni (image 1), which is a Wolffian duct remnant presenting as a simple cyst filled with serous fluid near the fimbriated ends of the fallopian tube.  

| Predisposing factors for fallopian tube torsion  
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Intrinsic factors</strong></td>
<td><strong>Extrinsic factors</strong></td>
<td></td>
</tr>
<tr>
<td>Congenital malformations (i.e. long mesosalpinx, hydatid cyst of Morgagni)</td>
<td>Paraovarian or paratubal mass</td>
<td></td>
</tr>
<tr>
<td>Hydrosalpinx</td>
<td>Uterine enlargement (i.e. pregnancy, tumor)</td>
<td></td>
</tr>
<tr>
<td>Tubal ligation</td>
<td>Adhesions (i.e. prior surgery, pelvic inflammatory disease, tuberculosis)</td>
<td></td>
</tr>
<tr>
<td>Tubal neoplasm</td>
<td>Hemodynamic alterations causing congestion and tortuosity of mesosalpingeal veins</td>
<td></td>
</tr>
<tr>
<td>Abnormal peristalsis or spasm (due to autonomic dysfunction or drugs)</td>
<td>Sudden changes in body position or trauma</td>
<td></td>
</tr>
<tr>
<td>Hypermobility</td>
<td>Increased tubal motility at midcycle</td>
<td></td>
</tr>
</tbody>
</table>

Table 1

**Clinical Presentation**

Fallopian tube torsion most commonly presents as lower abdominal or pelvic pain, which can radiate to the flank, thigh, or groin and can be accompanied by vomiting, vaginal bleeding, fever, tachycardia, and leukocytosis. Diagnosis can be challenging since there are no pathognomonic signs or symptoms for tubal torsion, and it can mimic appendicitis, ovarian torsion, and other common causes of abdominal pain. It more commonly occurs on the right than on the left, and is theorized to be due to the sigmoid colon and mesentery stabilizing the left fallopian tube. However, some believe that right tubal torsion is detected more often since patients with right-sided abdominal pain are imaged and surgically explored more frequently due to the concern for appendicitis.  

**Diagnostics**

There are no reliable imaging modalities to identify isolated fallopian tube torsion and the diagnosis is often made by laparoscopy. Sonography is frequently ordered to exclude ovarian torsion, and accurately predicts the diagnosis of fallopian tube torsion about 30% of the time. Findings in isolated tube torsion are non-specific and can include free fluid, a dilated tube with thickened walls, internal debris, an echogenic mass (representing the torsed tube), or impendence, absence, or reversal of diastolic blood flow with doppler. The “whirlpool sign,” which is seen in ovarian torsion and represents the twisted blood vessels of the torsed structure, has also been demonstrated in isolated fallopian tube torsion. CT scan or MRI may also be performed and can show tubal coiling, a torsion knot, infarction of the tubal walls, free fluid, peritubular fat stranding, thickening of the broad ligament, and regional ileus. May show a cystic mass or dilated tubular structure. Laboratory studies are usually within normal limits unless there is significant necrosis or ischemia.  

**Treatment**

Rapid treatment of fallopian tube torsion is essential, as it can lead to necrosis, gangrenous transformation, superinfection and peritonitis. Once there is a high enough clinical suspicion or a confirmed diagnosis via ultrasound, gynecology should be consulted for definitive management. Laparoscopy is the gold standard for both diagnosis and treatment of tubal torsion. Laparoscopic detorsion is the preferred management if there is low concern for tissue ischemia in order to preserve fertility. However, if the tube appears necrotic, salpingectomy should be performed.  

**Summary**

Isolated fallopian tube torsion is a rare diagnosis that should be considered in any female presenting with lower abdominal pain. Physical exam, laboratory and imaging studies are of limited utility to rule in the diagnosis, but always important for ruling out or decreasing suspicion for other pathology. The best imaging modality for detecting isolated fallopian tube torsion is ultrasound; however, the ultimate diagnosis is usually made with direct visualization by laparoscopy performed by our gynecology colleagues. Treatment consists of salpingectomy or, in the premenarchal or child-bearing population, surgical detorsion if possible in order to preserve fertility.  

**References**

Risk factor | Example of predisposing risk factors | Aspergillosis Manifestation
--- | --- | ---
Cavitary lung disease | Pulmonary tuberculosis, chronic obstructive pulmonary disease, sarcoidosis | Aspergiloma
Chronic lung disease | Allergic bronchopulmonary aspergillosis (ABPA), chronic obstructive pulmonary disease, lung transplant, recurrent lower respiratory tract infections | Chronic pulmonary aspergillosis
Immunocompromise | Neutropenia, bone marrow transplant, solid organ transplant, hematologic malignancy, immunodeficiency syndromes, prolonged steroid treatment or other immunosuppressants | Invasive pulmonary aspergillosis
Critical Illness | Prolonged ICU stay, severe lower respiratory tract infection, acute respiratory distress syndrome | Invasive pulmonary aspergillosis
Airway hypersensitivity | Asthma, cystic fibrosis (CF), blood eosinophil counts >500 cells/L | Allergic bronchopulmonary aspergillosis (ABPA)

Table 1: Spectrum of pulmonary aspergillosis by risk factor

Airway colonization by aspergillus species is common.13

Aspergilloma - Treatment

In the emergency department, treatment of an aspergilloma may involve initiation of an antifungal medication along with supportive care, especially if the patient has significant hemoptysis. Ultimately, surgical resection is the gold standard of treatment for symptomatic aspergillum, but many patients are poor candidates for surgery due to underlying lung disease, and morbidity and mortality with surgery is considerable.13 Bronchial artery embolization by interventional radiology is a potential treatment strategy for patients with moderate to severe hemoptysis who are poor surgical candidates.14

Systemic antifungal medications, including amphotericin B and azoles, have been used in patients with aspergilloma. Amphotericin B has been shown to have a cure rate of approximately 10%, which is similar to the rate of spontaneous resolution. A multicenter randomized clinical trial using itraconazole for 6 months demonstrated a cure rate of 63.4%. Voriconazole is an alternative therapy that has also shown efficacy in treatment of IPA and may have a higher threshold for fungal resistance.13,15 Currently, guidelines recommend treatment of chronic pulmonary aspergillosis, including aspergilloma, with at least 6 months of azole therapy.15,16 Echinocandins, such as micafungin, are also an option in patients who have previously not responded well to azoles.17

For patients who fail systemic therapy and are not surgical candidates, a few other treatment options remain. Endobronchial instillation of voriconazole has been effective, with 30.6% of patients reporting resolution of hemoptysis after one treatment and an additional 37.8% reporting resolution after the second treatment.18 Percutaneous intracavitary instillation of antifungals has also been used with some improvement. In some cases, bronchoscopic removal of the aspergilloma may be possible.13

Summary

Aspergillosis is disease primarily of the respiratory tract caused by Aspergillus species in patients with underlying risk factors such as immunosuppression and structural lung disease. Aspergiloma is one manifestation of aspergillosis, in which a fungal ball develops in a preexisting cavitary lung lesion. Aspergillosis can cause life-threatening hemoptysis. Treatment options include surgical resection, bronchial artery embolization, systemic antifungal therapy and direct antifungal instillation.

References


Spectrum of pulmonary aspergillosis
Summary

Chronic myelogenous leukemia is a hematologic malignancy associated with the Philadelphia chromosome and the Bcr-Abl1 protein. Patient presentations are varied and can include constitutional symptoms, bleeding, leukostasis, DIC, and TLS. Diagnosis is made using CBC, peripheral smear, bone marrow biopsy and cytopogenic testing in conjunction with hematology/oncology. ED management focuses on complications, with ultimate treatment including tyrosine kinase inhibitors, chemotherapy, and bone marrow transplant.

References


Polycythemia

Continued from page 7

toms are present in approximately one third of patients with PV at the time of diagnosis and can often precede other manifestations of the disease by months to years.3,4 Erythromelalgia is considered to be pathognomonic for PV and is described as an intense burning pain, often isolated to the hands and feet, associated with either rubor or pallor of those extremities.4 In patients with erythromelalgia, there is no evidence of neurovascular dysfunction.

Summary

Chronic myelogenous leukemia is a hematologic malignancy associated with the Philadelphia chromosome and the Bcr-Abl protein. Patient presentations are varied and can include constitutional symptoms, bleeding, leukostasis, DIC, and TLS. Diagnosis is made using CBC, peripheral smear, bone marrow biopsy and cytopogenic testing in conjunction with hematology/oncology. ED management focuses on complications, with ultimate treatment including tyrosine kinase inhibitors, chemotherapy, and bone marrow transplant.

Management and Disposition

Patients with relative polycythemia do not typically require further evaluation or admission for polycythemia alone. ED evaluation of patients with incidentally-discovered, asymptomatic absolute

Blast Crisis

Continued from page 5

it is important to evaluate for secondary complications such as disseminated intravascular coagulation (DIC), tumor lysis syndrome (TLS), bleeding from thrombocytopenia, and end-organ damage from leukostasis. An infectious workup may also be warranted, given that these patients are at higher risk for infection with dysfunctional circulating immune cells and possible functional asplenia.16,18

Treatment

Treatment of CML in the ED should focus on management of serious complications in consultation with hematology-oncology. The most common causes of death in patients with CML in blast phase are infection due to functional neutropenia, and hemorrhage due to thrombocytopenia or DIC.16,21 Thus, aggressive evaluation and management of infectious sources should be undertaken, and transfusion of blood products should be discussed with hematology-oncology to define appropriate transfusion thresholds. In some cases, transfusion of blood products worsens hyperviscosity and should be avoided.16

In patients with hyperleukocytosis, cytoreduction should be initiated to mitigate end-organ damage from leukostasis.16 Treatment options (other than induction chemotherapy) include hydroxyurea, intravenous fluids, and leuprolide.18,19,20 Hydroxyurea is a cytoductive agent that serves as bridge to definitive therapy in reducing circulating leukocytes.20 Fluids can be used for rehydration and decreasing blood viscosity. Leukapheresis can effectively lower the WBC count from 10-70% after just one treatment, but its effects on morbidity and mortality are uncertain.19 In addition, leukapheresis involves multiple risks including anticoagulation, hypocalcemia, worsening of thrombocytopenia, and the need for central venous access, and as such, it is a treatment that can be considered but not routinely recommended.16 Dexamethasone is also frequently used as an adjunct to reduce inflammatory effects.16

Definitive treatment for CML involves tyrosine kinase inhibitors (TKIs), which target the pathologic BCR-ABL tyrosine kinase through competitive inhibition at ATP binding sites.2 The advent of this therapy in 1999 has revolutionized the treatment of CML and greatly improved its prognosis, reducing progression from CML chronic phase (CP) to CML blast phase(BP) from 20% annually to 1-3% annually.14 Imatinib, one of the first TKIs to be developed, has been largely replaced by other agents such as nilotinib and dasatinib.21 CML-BP often involves a combination of TKI and additional chemotherapy, and intrathelial prophylaxis is indicated given the high risk for occult central nervous system involvement and subsequent relapse.16 Most patients who progress to CML-BP require bone marrow transplant.16


15
Patients with polycythemia have up to a 28% incidence of thrombotic events and an approximately 8% chance of a major hemorrhage related to their disease. Therefore, admission is appropriate for symptomatic patients, either with hallmark signs of PV or with hyperviscosity symptoms, and for patients with hematocrit >60%dl. These patients can be started on low-dose aspirin in the emergency department, which provides symptomatic relief and decreases the thrombotic risk.

Acute thromb in patients with polycythemia are managed similarly to patients who lack this risk factor, with the exception of phlebotomy. Phlebotomy is indicated for patients with thrombotic complications and to maintain normal hematocrit levels in patients with primary polycythemias. While the need for phlebotomy may be an indication for admission, it is generally considered to be outside the scope of practice of an emergency physician. General guidance suggests that during the diagnostic workup phase, phlebotomy can be used to lower hematocrit levels to <60% until definitive diagnosis is reached, after which target hematocrit should be approximately 45%. Phlebotomy treatments involve the removal of large quantities of blood, usually 250-500 cc, followed by 1:1 replacement with a crystalloid fluid. Conventional wisdom is that the expected reduction in hematocrit is three percentage points per 500ml blood removed. Dual-anti-platelet agents are not routinely recommended in patients with polycythemia due to an increased risk of hemorrhage, but there is some evidence that this may be helpful in certain patients.

### Summary

Polycythemia is most frequently found incidentally, and can be relative or absolute. Absolute polycythemia has both primary and secondary causes, and if left unmanaged can cause symptoms of hyperviscosity and increased risk of thrombotic events. Treatment depends on the underlying cause and may include anti-platelet agents and phlebotomy.

### References